Pfizer (PFE) Announces Data Published in NEJM Shows its Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

Go back to Pfizer (PFE) Announces Data Published in NEJM Shows its Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

Data Published in New England Journal of Medicine Shows Pfizer’s Tofacitinib Meets Primary Endpoint in Brazilian Study in Patients Hospitalized with COVID-19 Pneumonia

June 16, 2021 5:19 PM EDT

Trial demonstrates cumulative incidence of death or respiratory failure through day 28 was 18.1% (26 of 144) with tofacitinib compared to 29.0% (42 of 145) with placebo, in hospitalized patients with COVID-19 pneumonia   Multi-center, randomized, double-blind, placebo-controlled trial conducted across 15 sites in Brazil Tofacitinib is not approved or authorized for the treatment of COVID-19 patients. Tofacitinib should not be used in patients with an active serious infection

NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and The Academic Research Organization (ARO) from the Hospital Israelita Albert Einstein today announced that the... More